Fertility preservation after chemotherapy for Hodgkin lymphoma.

Management of fertility in patients treated for Hodgkin's lymphoma. Haematologica (2011) 0.89

Sexual dysfunction and infertility as late effects of cancer treatment. EJC Suppl (2014) 0.87

AMH/MIS as a contraceptive that protects the ovarian reserve during chemotherapy. Proc Natl Acad Sci U S A (2017) 0.85

Fertility considerations in young women with hematological malignancies. J Assist Reprod Genet (2012) 0.84

Hodgkin lymphoma, version 2.2015. J Natl Compr Canc Netw (2015) 0.82

Fertility-preserving treatment options in patients with malignant hematological diseases. Turk J Haematol (2012) 0.81

Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells. PLoS One (2013) 0.79

Fertility preservation strategies for male patients with cancer. Nat Rev Urol (2013) 0.78

Curcuma Contra Cancer? Curcumin and Hodgkin's Lymphoma. Cancer Growth Metastasis (2013) 0.78

Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol (2011) 0.75

Study of the prevalence of azoospermia in patients with Hodgkin's lymphoma prior to treatment. Adv Biomed Res (2013) 0.75

Knowledge, attitudes, and practices of hematologists regarding fertility preservation in Turkey. Turk J Haematol (2013) 0.75

Process and Pitfalls of Sperm Cryopreservation. J Clin Med (2017) 0.75

In vitro fertilization with preimplantation genetic screening. N Engl J Med (2007) 5.26

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood (2007) 5.18

Double-hit B-cell lymphomas. Blood (2010) 3.19

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood (2004) 2.50

High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol (2003) 1.84

Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood (2009) 1.84

High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost (2009) 1.64

The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha. Haematologica (2005) 1.58

Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function. Nephrol Dial Transplant (2010) 1.42

Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol (2006) 1.42

Long-term quality of VKA treatment and clinical outcome after extreme overanticoagulation in 14,777 AF and VTE patients. Thromb Haemost (2014) 1.40

Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol (2004) 1.28

Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood (2005) 1.28

The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus. Blood (2004) 1.20

Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study. Haematologica (2006) 1.15

High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol (2008) 1.10

Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol (2014) 1.10

Identification of RUNX1/AML1 as a classical tumor suppressor gene. Oncogene (2003) 1.08

Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood (2004) 1.08

High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. Cancer Treat Rev (2007) 1.07

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma (2012) 1.07

Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study. J Clin Oncol (2011) 0.97

Syndromic aspects of testicular carcinoma. Cancer (2003) 0.96

Treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone is beneficial but toxic in very elderly patients with diffuse large B-cell lymphoma: a population-based cohort study on treatment, toxicity and outcome. Leuk Lymphoma (2013) 0.95

Perinatal outcome in singletons after modified natural cycle IVF and standard IVF with ovarian stimulation. Eur J Obstet Gynecol Reprod Biol (2010) 0.95

Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant (2005) 0.94

Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol (2007) 0.94

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood (2008) 0.92

The European Society of Human Reproduction and Embryology guideline for the diagnosis and treatment of endometriosis: an electronic guideline implementability appraisal. Implement Sci (2011) 0.92

HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation (2005) 0.90

Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B cells to fas-induced apoptosis. J Immunol (2007) 0.90

In normal controls, both age and gender affect coagulability as measured by thrombelastography. Anesth Analg (2010) 0.90

The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD). Blood (2010) 0.86

Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification. Br J Haematol (2005) 0.85

Comorbidity is an independent prognostic factor in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP: a population-based cohort study. Br J Haematol (2014) 0.84

PGD for hereditary breast and ovarian cancer: the route to universal tests for BRCA1 and BRCA2 mutation carriers. Eur J Hum Genet (2013) 0.83

Sperm quality before treatment in patients with early stage Hodgkin's lymphoma enrolled in EORTC-GELA Lymphoma Group trials. Haematologica (2009) 0.83

Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. Clin Lymphoma Myeloma (2005) 0.83

Haemostatic variables during normal menstrual cycle. A systematic review. Thromb Haemost (2011) 0.82

Associations between high factor VIII and low free protein S levels with traditional arterial thrombotic risk factors and their risk on arterial thrombosis: results from a retrospective family cohort study. Thromb Res (2010) 0.81

Lipid levels do not influence the risk of venous thromboembolism. Results of a population-based cohort study. Thromb Haemost (2012) 0.81

Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 10th annual conference of the European Mantle Cell Lymphoma Network. Leuk Lymphoma (2011) 0.81

Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. J Clin Oncol (2005) 0.81

Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. Ann Hematol (2004) 0.81

The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes. Ann Intern Med (2006) 0.81

An improved flow cytometric method using FACS Lysing Solution for measurement of ZAP-70 expression in B-cell chronic lymphocytic leukemia. Cytometry B Clin Cytom (2008) 0.81

The European Competence Network on Mastocytosis (ECNM). Wien Klin Wochenschr (2004) 0.81

Serum syndecan-1 in patients with newly diagnosed monoclonal proteinemia. Haematologica (2005) 0.80

European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wien Klin Wochenschr (2012) 0.80

Increased risk of arterial thromboembolism after a prior episode of venous thromboembolism: results from the Prevention of REnal and Vascular ENd stage Disease (PREVEND) Study. Br J Haematol (2012) 0.80

Embryo quality and impact of specific embryo characteristics on ongoing implantation in unselected embryos derived from modified natural cycle in vitro fertilization. Fertil Steril (2009) 0.80

Active cytomegalovirus infection in patients with acute venous thrombosis: a case-control study. Am J Hematol (2011) 0.80

Management of mantle cell lymphoma in the elderly patient. Clin Interv Aging (2013) 0.79

Thrombocytopenia affects plasmatic coagulation as measured by thrombelastography. Blood Coagul Fibrinolysis (2010) 0.79

Elevated albuminuria associated with increased risk of recurrent venous thromboembolism: results of a population-based cohort study. Br J Haematol (2012) 0.79

Genome wide molecular analysis of minimally differentiated acute myeloid leukemia. Haematologica (2009) 0.79

Characterisation of hairy cell leukaemia by tiling resolution array-based comparative genome hybridisation: a series of 13 cases and review of the literature. Eur J Haematol (2010) 0.79

The prevalence of underlying bleeding disorders in patients with heavy menstrual bleeding with and without gynecologic abnormalities. Am J Obstet Gynecol (2013) 0.79

The risk of postpartum hemorrhage in women using high dose of low-molecular-weight heparins during pregnancy. Thromb Res (2012) 0.78

Temporal and developmental-stage variation in the occurrence of mitotic errors in tripronuclear human preimplantation embryos. Biol Reprod (2013) 0.78

Effects of red blood cells on hemostasis. Transfusion (2010) 0.78

Lenalidomide therapy in systemic mastocytosis. Leuk Res (2008) 0.78

Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. Br J Haematol (2008) 0.76

Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys (2006) 0.76

Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study. J Clin Oncol (2012) 0.76

Modified natural cycle versus controlled ovarian hyperstimulation IVF: a cost-effectiveness evaluation of three simulated treatment scenarios. Hum Reprod (2013) 0.75

Splenectomy and second malignancies in patients with Hodgkin lymphoma. Leuk Lymphoma (2014) 0.75

The role of B cell-mediated T cell costimulation in the efficacy of the T cell retargeting bispecific antibody BIS20x3. J Immunol (2004) 0.75

Treatment and survival of patients with thyroid lymphoma: a population-based study with clinical and pathologic reviews. Clin Lymphoma Myeloma (2005) 0.75

Clinical and pathological features of testicular diffuse large B-cell lymphoma: a heterogeneous disease. Leuk Lymphoma (2011) 0.75

Decreased free protein S levels and venous thrombosis in the acute setting, a case-control study. Thromb Res (2011) 0.75

PROS1 Heerlen polymorphism is associated with increased free plasma tissue factor pathway inhibitor levels. Thromb Haemost (2012) 0.75

Pain and anxiety during bone marrow biopsy. Pain Manag Nurs (2011) 0.75

A 'pre-induction course' with non-cross-reacting cytostatic drugs for rapid tumour load reduction improves outcome in adult acute lymphoblastic leukaemia. Br J Haematol (2007) 0.75

Biochemical markers predictive for bone marrow involvement in systemic mastocytosis. Haematologica (2008) 0.75

Low cut-off values increase diagnostic performance of protein S assays. Thromb Haemost (2010) 0.75

Cost analysis of common treatment options for indolent follicular non-Hodgkin's lymphoma. Haematologica (2005) 0.75

[IVF in a modified natural cycle]. Ned Tijdschr Geneeskd (2010) 0.75

Routine evaluation and treatment of unexplained menorrhagia: do we consider haemostatic disorders? Eur J Obstet Gynecol Reprod Biol (2010) 0.75

Analysis of biomarker expression in severe endometriosis and determination of possibilities for targeted intraoperative imaging. Int J Gynaecol Obstet (2013) 0.75